GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » Profitability Rank

ASEP Medical Holdings (ASEP Medical Holdings) Profitability Rank : 2 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings Profitability Rank?

ASEP Medical Holdings has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

ASEP Medical Holdings's Operating Margin % for the quarter that ended in Dec. 2023 was -8,737.50%. As of today, ASEP Medical Holdings's Piotroski F-Score is 4.


Competitive Comparison of ASEP Medical Holdings's Profitability Rank

For the Biotechnology subindustry, ASEP Medical Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ASEP Medical Holdings's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where ASEP Medical Holdings's Profitability Rank falls into.



ASEP Medical Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

ASEP Medical Holdings has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ASEP Medical Holdings's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-1.398 / 0.016
=-8,737.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

ASEP Medical Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


ASEP Medical Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Traded in Other Exchanges
Address
730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7
ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.